Literature DB >> 22969190

Use of butyrate or glutamine in enema solution reduces inflammation and fibrosis in experimental diversion colitis.

Rodrigo Goulart Pacheco1, Christiano Costa Esposito, Lucas C M Müller, Morgana T L Castelo-Branco, Leonardo Pereira Quintella, Vera Lucia A Chagas, Heitor Siffert P de Souza, Alberto Schanaider.   

Abstract

AIM: To investigate whether butyrate or glutamine enemas could diminish inflammation in experimental diversion colitis.
METHODS: Wistar specific pathogen-free rats were submitted to a Hartmann's end colostomy and treated with enemas containing glutamine, butyrate, or saline. Enemas were administered twice a week in the excluded segment of the colon from 4 to 12 wk after the surgical procedure. Follow-up colonoscopy was performed every 4 wk for 12 wk. The effect of treatment was evaluated using video-endoscopic and histologic scores and measuring interleukin-1β, tumor necrosis factor-alpha, and transforming growth factor beta production in organ cultures by enzyme linked immunosorbent assay.
RESULTS: Colonoscopies of the diverted segment showed mucosa with hyperemia, increased number of vessels, bleeding and mucus discharge. Treatment with either glutamine or butyrate induced significant reductions in both colonoscopic (P < 0.02) and histological scores (P < 0.01) and restored the densities of collagen fibers in tissue (P = 0.015; P = 0.001), the number of goblet cells (P = 0.021; P = 0.029), and the rate of apoptosis within the epithelium (P = 0.043; P = 0.011) to normal values. The high levels of cytokines in colon explants from rats with diversion colitis significantly decreased to normal values after treatment with butyrate or glutamine.
CONCLUSION: The improvement of experimental diversion colitis following glutamine or butyrate enemas highlights the importance of specific luminal nutrients in the homeostasis of the colonic mucosa and supports their utilization for the treatment of human diversion colitis.

Entities:  

Keywords:  Butyrate; Cytokines; Diversion colitis; Glutamine; Short-chain fatty acids

Mesh:

Substances:

Year:  2012        PMID: 22969190      PMCID: PMC3436042          DOI: 10.3748/wjg.v18.i32.4278

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  48 in total

1.  A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon.

Authors:  Aldo Roda; Patrizia Simoni; Maria Magliulo; Paolo Nanni; Mario Baraldini; Giulia Roda; Enrico Roda
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

2.  Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2.

Authors:  Arianne L Theiss; James G Simmons; Christian Jobin; P Kay Lund
Journal:  J Biol Chem       Date:  2005-09-01       Impact factor: 5.157

3.  Tumor necrosis factor alpha reduces butyrate oxidation in vitro in human colonic mucosa: a link from inflammatory process to mucosal damage?

Authors:  Stéphane Nancey; Driffa Moussata; Ivan Graber; Sylvette Claudel; Jean-Christophe Saurin; Bernard Flourié
Journal:  Inflamm Bowel Dis       Date:  2005-06       Impact factor: 5.325

4.  Butyrate enemas improve intestinal anastomotic strength in a rat model.

Authors:  Johanne G Bloemen; Marc H Schreinemacher; Adriaan P de Bruine; Wim A Buurman; Nicole D Bouvy; Cornelis H Dejong
Journal:  Dis Colon Rectum       Date:  2010-07       Impact factor: 4.585

Review 5.  The fundamental basis of inflammatory bowel disease.

Authors:  Warren Strober; Ivan Fuss; Peter Mannon
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 6.  Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency.

Authors:  Ronan Thibault; François Blachier; Béatrice Darcy-Vrillon; Pierre de Coppet; Arnaud Bourreille; Jean-Pierre Segain
Journal:  Inflamm Bowel Dis       Date:  2010-04       Impact factor: 5.325

7.  Proctitis and colitis following diversion of the fecal stream.

Authors:  D J Glotzer; M E Glick; H Goldman
Journal:  Gastroenterology       Date:  1981-03       Impact factor: 22.682

Review 8.  Butyrate and the colonocyte. Production, absorption, metabolism, and therapeutic implications.

Authors:  O C Velázquez; H M Lederer; J L Rombeau
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

9.  Impaired bacterial flora in human excluded colon.

Authors:  C Neut; J F Colombel; F Guillemot; A Cortot; P Gower; P Quandalle; M Ribet; C Romond; J C Paris
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

10.  Comparison of prophylactic and therapeutic use of short-chain fatty acid enemas in diversion colitis: a study in Wistar rats.

Authors:  Ariano Jose Freitas de Oliveira; Francisco Edilson Leite Pinto Júnior; Maria Célia Carvalho Formiga; Syomara Pereira da Costa Melo; Jose Brandao-Neto; Ana Maria de Oliveira Ramos
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

View more
  22 in total

1.  Prophylactic tributyrin treatment mitigates chronic-binge ethanol-induced intestinal barrier and liver injury.

Authors:  Gail A Cresci; Bryan Glueck; Megan R McMullen; Wei Xin; Daniella Allende; Laura E Nagy
Journal:  J Gastroenterol Hepatol       Date:  2017-09       Impact factor: 4.029

2.  Energy, oxidative stress, and inflammation in the colon.

Authors:  Richard F Harty
Journal:  Dig Dis Sci       Date:  2013-12       Impact factor: 3.199

Review 3.  The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications.

Authors:  Jason R Goldsmith; R Balfour Sartor
Journal:  J Gastroenterol       Date:  2014-03-21       Impact factor: 7.527

4.  Claudin-3 and occludin tissue content in the glands of colonic mucosa with and without a fecal stream.

Authors:  Carlos Augusto Real Martinez; Fabio Guilherme Caserta Maryssael de Campos; Viviel Rodrigo José de Carvalho; Caroline de Castro Ferreira; Murilo Rocha Rodrigues; Daniela Tiemi Sato; José Aires Pereira
Journal:  J Mol Histol       Date:  2015-02-04       Impact factor: 2.611

5.  Successful autologous fecal transplantation for chronic diversion colitis.

Authors:  F Gundling; M Tiller; A Agha; W Schepp; I Iesalnieks
Journal:  Tech Coloproctol       Date:  2014-10-10       Impact factor: 3.781

6.  Removal of the cecum affects intestinal fermentation, enteric bacterial community structure, and acute colitis in mice.

Authors:  Kirsty Brown; D Wade Abbott; Richard R E Uwiera; G Douglas Inglis
Journal:  Gut Microbes       Date:  2018-03-13

Review 7.  Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity.

Authors:  Jessica Soldavini; Jonathan D Kaunitz
Journal:  Dig Dis Sci       Date:  2013-07-10       Impact factor: 3.199

8.  Eicosatetraynoic Acid and Butyrate Regulate Human Intestinal Organoid Mitochondrial and Extracellular Matrix Pathways Implicated in Crohn's Disease Strictures.

Authors:  Ingrid Jurickova; Erin Bonkowski; Elizabeth Angerman; Elizabeth Novak; Alex Huron; Grayce Akers; Kentaro Iwasawa; Tzipi Braun; Rotem Hadar; Maria Hooker; Sarah Han; David J Cutler; David T Okou; Subra Kugathasan; Anil Jegga; James Wells; Takanori Takebe; Kevin P Mollen; Yael Haberman; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2022-07-01       Impact factor: 7.290

Review 9.  Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.

Authors:  Si-Nan Lin; Ren Mao; Chenchen Qian; Dominik Bettenworth; Jie Wang; Jiannan Li; David H Bruining; Vipul Jairath; Brian G Feagan; Min-Hu Chen; Florian Rieder
Journal:  Physiol Rev       Date:  2021-09-27       Impact factor: 37.312

10.  Serological Biomarkers and Diversion Colitis: Changes after Stimulation with Probiotics.

Authors:  Ángela Rodríguez-Padilla; Germán Morales-Martín; Rocío Pérez-Quintero; Juan Gómez-Salgado; Carlos Ruiz-Frutos
Journal:  Biomolecules       Date:  2021-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.